Thus, using the observed 14% ATM variant frequency (PV and/or VUS) and hazard ratio of 0.5, we estimate that approximately 1400 patients with NSCLC who have brain metastases would be required to detect a statistically significant difference in LIP after SRS. This evidence concerns the gene ATM and non-small cell lung carcinoma.